colorectal_cancer_blaversjon

Målrettet personlig 1. linjebehandling: Median ~ 6 måneder lengre overlevelse for pasienter med

wtRAS mCRC* Vectibix (panitumumab) er rabattert gjennom LIS

2. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 2014;32(21):2240-7. PEAK (fase 2-studie), median overlevelse: 2 Vectibix + FOLFOX : 41,3 måneder Bevacizumab + FOLFOX: 28,9 måneder HR = 0.63 (95% CI: 0.39-1.02) P = 0.058

* PRIME-studie, median overlevelse: 1

1. Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab- FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34. Vectibix + FOLFOX vs. FOLFOX: ~ 6 måneder (26 vs 20,2 mnd) HR = 0.78 (95% CI: 0.62-0.99) P = 0.043

Made with